Clinical Trial Search

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day

Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01

Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074

Primary: Percent Change in Urine Protein/Creatinine (Up/C) — -44.8; -18.5; -47.4; -33.1 percent change

Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491

Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants

Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009

Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…

Primary: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at the Indicated Time Points — 0; 1; 0; 0 Participants

Primary: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up Through 3 Months Post Transplant…

Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…

Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg

Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g

Primary: Percent Change From Baseline in UPCR — -47.7; -47.5; -47.6 percent change

Primary: Changes in Proteinuria (With Stable Renal Function) — 7.6; 7.27 g/day — p=0.49

Primary: Change From Baseline in UPCR at Week 12 — 0.83; 1.02; 1.12; 0.87 g protein/g creatinine — p=0.1924

Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants

Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio

Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: Percentage of Complete Remission — 4; 3 Participants

Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants

Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²

Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24

Primary: Change in eGFR From Baseline at Week 48 — -2.83; -2.37; -4.07; -3.20 mL/min/1.73 m^2 — p=0.755

Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7

Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale

Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm

Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005